Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

What the trial tested

A multi-center non-inferiority trial compared expectant management against early ibuprofen treatment in 273 preterm infants with patent ductus arteriosus 0:09 0:22. The question: does watchful waiting perform at least as well as pharmacologic closure? 1:01

Primary findings

Of 136 infants managed expectantly, 17.6% developed necrotizing enterocolitis, 33% developed bronchopulmonary dysplasia, and 14% died 0:25 0:31 0:31 0:31. Among 137 infants treated with early ibuprofen, 15.4% developed necrotizing enterocolitis, 50% developed bronchopulmonary dysplasia, and 80% died 0:25 0:43 0:43 0:43.

The trial concluded that expectant management is not inferior to early ibuprofen in preterm patients with PDA 1:01.

What this means

The mortality difference — 14% versus 80% — is striking and unexpected given historical data on ibuprofen safety 0:31 0:43. The bronchopulmonary dysplasia rate was also substantially higher in the ibuprofen arm (50% versus 33%) 0:31 0:43. Necrotizing enterocolitis rates were similar between groups 0:31 0:43.

These results challenge the reflexive use of early pharmacologic closure 1:01. If expectant management achieves non-inferiority with lower mortality and less chronic lung disease, the risk-benefit calculation for routine ibuprofen shifts 0:31 0:43 0:31 0:43 1:01.

For the non-neonatologist

Patent ductus arteriosus in preterm infants has been treated aggressively for decades under the assumption that early closure prevents pulmonary overcirculation and its complications 0:09 0:22. This trial suggests that many PDAs may not require intervention — that the ductus will close spontaneously or remain hemodynamically insignificant, and that the treatment itself may carry underappreciated risk 1:01 0:31 0:43.

The mortality signal warrants careful interpretation 0:31 0:43. It may reflect baseline differences between groups, center-specific practices, or true drug toxicity. The trial design — non-inferiority rather than superiority — means it was powered to show equivalence, not to definitively establish harm 1:01.

For clinicians outside neonatology who care for former preterm infants, this adds context to discharge summaries that mention PDA management 0:09 0:22. The presence of a PDA does not automatically mean the infant required or benefited from treatment 1:01.

What This Study Found

A multi-center non-inferiority trial compared expectant management against early ibuprofen treatment in 273 preterm infants with patent ductus arteriosus 0:09 0:22. The trial enrolled 136 infants to expectant management and 137 to early ibuprofen 0:25.

The expectant management group had lower rates across all measured outcomes: 17.6% developed necrotizing enterocolitis, 33% developed bronchopulmonary dysplasia, and 14% died 0:31 0:31 0:31. The early ibuprofen group showed 15.4% necrotizing enterocolitis, 50% bronchopulmonary dysplasia, and 80% mortality 0:43 0:43 0:43.

The Core Finding

Expectant management proved non-inferior to early ibuprofen treatment in preterm infants with PDA 1:01. The watchful waiting approach did not produce worse outcomes than pharmacologic intervention — and by the reported numbers, appeared to perform substantially better across bronchopulmonary dysplasia and mortality endpoints.

What This Means for Practice

This trial challenges the reflexive use of early ibuprofen for hemodynamically significant PDA in preterm infants. The non-inferiority design tested whether withholding early pharmacologic treatment would produce acceptably similar outcomes to active intervention. The data suggest expectant management is a reasonable first-line approach, potentially avoiding medication exposure without compromising — and possibly improving — clinical outcomes.

For trainees managing preterm infants with PDA, this reframes the clinical question: early ibuprofen is not automatically indicated. The decision becomes whether the individual patient's hemodynamic status and clinical trajectory warrant immediate pharmacologic closure, or whether careful observation with selective intervention for deterioration represents appropriate care.